

Method for efficient transfection of *in vitro*-transcribed mRNA into SK-N-AS and HEK293 cells: Difference in the toxicity of nuclear EGFP compared to cytoplasmic EGFP

KATARINA EJESKÄR^{1,2}, SUSANNE FRANSSON², FATEN ZAIBAK¹ and PANAYIOTIS A. IOANNOU¹

¹Murdoch Children's Research Institute, Melbourne University, Royal Children's Hospital, 3052 Parkville, VIC, Australia;

²Department of Clinical Genetics, Göteborg University, SU/Östra, SE-416 85 Gothenburg, Sweden

Received December 2, 2005; Accepted January 20, 2006

Abstract. Here we report a method for efficient transfection of *in vitro*-transcribed mRNA into two different types of human adherent cells, the neuroblastoma cell line SK-N-AS, and the transformed kidney cell line HEK293. By using newly trypsinized adherent cells in suspension and Lipofectamine™ 2000, we detected a transfection efficiency of 80-90% in both cell lines and a cell viability of 90% in SK-N-AS and 60% in HEK293, 24 h after transfection when using cytoplasmic enhanced green fluorescent protein (EGFP)-mRNA. We have evaluated the different effects of the generally used EGFP that mainly localizes to the cytoplasm and nuclear EGFP, where the nuclear EGFP are more toxic to the cells than the cytoplasmic EGFP. In order to develop a null experiment, we constructed a short non-functional mRNA including a nuclear localization signal and evaluated the concentrations at which mRNA encoding nuclear proteins can be added without a general toxicity, depending on the fact that the proteins are localized to the nucleus. For both SK-N-AS and HEK293 cells, a concentration of up to 100 ng mRNA in 10⁵ cells, encoding a nuclear protein with no other function, did not affect the cells. For evaluation of the method, we screened four different human mRNAs, *PDG*, *DFFA*, *CORT* and *PEX14*, for their ability to affect cell proliferation in these cells. *PEX14* was the only gene that significantly ($p=0.03$) reduced cell proliferation for both cell types, *DFFA* significantly ($p=0.04$) reduced cell proliferation in SK-N-AS but not in HEK293 cells. *PDG* and *CORT* did not have any effect on cell proliferation. We have developed an easy method for efficient delivery of *in vitro*-transcribed mRNA into the adherent cell lines, SK-N-AS and HEK293. This method is useful for a quick screening of how different genes affect cell proliferation.

Introduction

A major challenge today is to analyze the functions of many genes at the cellular level (1). It is possible to conduct high-throughput screening through transfectional microarrays (2) but, for many research groups, this is not an option because it requires costly equipment and, for many research projects, it might not be necessary to test thousands of genes.

The major issue in functional gene studies in living cells is good transfection efficiency, and there are numerous different methods for DNA/RNA delivery available, all with advantages and drawbacks (3). Every cell type seems to prefer different methods for effective transfection, and it also depends on the size of the DNA or RNA-molecule that the study aims to deliver. One widely used method is delivery by cationic lipids, for which, again, a wide range of different compounds is available, all with different qualities (4,5). Lipofectamine™ 2000 (Invitrogen) is a widely used cationic lipid that has been shown to be an effective transfection agent for both DNA and RNA delivery (6). Easy and robust follow-up methodology and good and reliable null-function tests for comparison of experiments is also important.

Many transfection protocols are based on the use of cDNA-expression vectors; with promoters depending on the cells own transcription machinery. The transfected cDNA-vector often has an uneven distribution between cells, resulting in substantial variation in the level of delivered gene product in each cell. This might partly be due to the very strong promoters used in these vectors, thus the difference in copy number in each cell does not need to be very large to result in a major difference in the gene product produced. Another obstacle in DNA-expression vector delivery is the need for the transfected DNA to enter the nucleus for gene transcription, and this is the main difficulty in obtaining high DNA-transfection efficiency (7,8). One way to overrule these problems is to use *in vitro*-transcribed mRNA, since this does not need to enter the nucleus in order to be translated into protein (9,10). *In vitro* mRNA transfection has also been shown to have a high transfection efficiency and low toxicity in a number of different cell types, including embryonic stem cells and T-cells (11,12).

One common way to detect and calculate transfection efficiency is to use an easily detected gene product, and one

Correspondence to: Dr Katarina Ejeskär, Department of Clinical Genetics, Göteborg University, Sahlgrenska University Hospital/East, SE-416 85 Gothenburg, Sweden
E-mail: katarina.ejeskar@clingen.gu.se

Key words: transfection, *in vitro* mRNA, SK-N-AS, HEK293, enhanced green fluorescent protein, nuclear localization signal, cell proliferation assay

of the easiest and most widely used is green fluorescent protein (GFP) (13). In order to obtain a more precise detection, we used enhanced green fluorescent protein (EGFP), which is a unique GFP variant which contains chromophore mutations that make the protein 35 times brighter than wild-type GFP and is codon-optimized for higher expression in mammalian cells (14).

A nuclear localization signal (NLS) is a peptide sequence that forces the protein (or DNA) into the nucleus (15). There are many different types of NLS; in this study, we have used SV40-NLS (MVPKPKKRVKVED).

In order to evaluate the method with human gene products, we have used four different mRNAs (*PDG*, *DFFA*, *CORT* and *PEX14*), all mapped to the same region on chromosome 1p (1p36.2) (16-19). *PGD* (6-phosphogluconate dehydrogenase) is an enzyme in the pentose phosphate shunt. *DFFA* (DNA fragmentation factor 45 kDa α) is a substrate for caspase-3 and triggers DNA fragmentation during apoptosis, it is a cytosolic protein that relocates to the nucleus when activated (20). *CORT* (cortistatin precursor) is a secreted neuropeptide that belongs to the somatostatin family (21). *PEX14* (peroxisomal biogenesis factor 14) is a protein bound to the peroxisomal membrane, importing PTS1-containing proteins to the peroxisome (22,23), it has also been shown to interact with nuclear factor erythroid-2 (*NFE2*) to inhibit transcriptional activation (19).

In this report, we present a method to effectively transfect *in vitro*-transcribed mRNA into the widely used human embryonic kidney cell line, HEK293, known to function as a good transient expression system (24), and the human neuroblastoma cell line, SK-N-AS. We also present data on the major difference in sensitivity to nuclear EGFP and cytoplasmic EGFP in these cells. In order to evaluate the effect of nuclear proteins, we developed a small non-functional peptide including a nuclear localization signal (NLS) for use in null experiments. For evaluation of the method, we screened four different human mRNAs (*PDG*, *DFFA*, *CORT* and *PEX14*) for their ability to affect cell proliferation in these cells.

Materials and methods

***In vitro* mRNA.** DNA fragments of the coding region of the EGFP-gene linked to the Sp6 promoter sequence and a polyA tail at the end of the fragment was constructed by PCR using the NLS-EGFP forward primer 5'-ATTTAGGTGACACTATAGAAGTGCGCCACCATGGTTCCGAAGAAAAAACGTAAAGTTGAGGATCCGATGGTGAGCAAGGGCGAGG-3' and NLS-EGFP reverse primer 5'-GG(T)₃₀CAGCGAGCTCTAGGGCCGC-3' for NLS-EGFP mRNA (nuclear); and the NLS-EGFP forward primer and NLS-nonsense reverse primer 5'-GG(T)₃₀CGACCAGGATGGGCACTTACCCGGTGAACAGC-3' for the nonsense-NLS PCR product; using pIRES-EGFP-vector as a template. PCR was performed using Hi Fidelity Taq (Roche) according to the supplier's protocol with an annealing temperature of 58°C and 25 cycles of PCR. Cytoplasmic EGFP-mRNA was produced using an *EcoRI*-digested Sp6-EGFP-vector as template in the *in vitro* mRNA reaction.

Full-length IMAGE cDNA clones of the genes, *DFFA* (GenBank: BC000037), *PEX14* (GenBank: BC006327), and

PGD (GenBank: BC000368) (HGMP Resource Centre, UK), and a clone for *CORT* (GenBank: AF013252) (Incyte Genomics, Palo Alto, CA) were used as templates to make a full-length PCR product. DNA fragments containing the coding region of the genes linked to the Sp6 promoter sequence and a polyA tail at the end of the fragment was constructed by PCR using gene specific primers with the Sp6-sequence (ATTTAGGTGACACTATAGAAGTG) added to the forward primer, and a poly (T)₃₀ to the reverse primer. Primer sequences are available upon request.

The PCR product (500 ng) was used as a template for *in vitro* mRNA using mMACHINE mMACHINE (Ambion). The procedure was according to supplier's protocol using 4-h incubation at 37°C. The mRNA was DnaseI-treated for 15 min at 37°C and LiCl-precipitated. The concentration of mRNA was measured by spectrophotometry while integrity and length was evaluated by agarose gel electrophoresis.

Tissue culture. The neuroblastoma cell line, SK-N-AS (ECACC), and the kidney derived cell line, HEK293 (ATCC), were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS) supplemented with L-glutamine, at 37°C using standard procedures. One day before any transfection experiment the cell lines were split into new culture flasks; cells with 60-80% confluence were used in transfection experiments.

Immediately before the transfection procedure, the cells were trypsinized and washed twice with PBS and the viable cell numbers were calculated using trypan blue staining.

Transfection of mRNA. Transfection was performed on newly trypsinized cells in suspension in a 12-well plate, using 2x10⁵ cells/well in 1 ml DMEM with 10% FCS/well for SK-N-AS and 10⁵ cells for HEK293. For each transfection, different amounts of mRNA (Fig. 3) and 1 μ l Lipofectamine™ 2000 (Invitrogen) were used. The mRNA and the Lipofectamine 2000 were incubated for 30 min in 100 μ l OPTI-MEM (Gibco) before being added to the cell suspensions. The cell and Lipofectamine 2000-mRNA complex mix were immediately divided into 96-well plates, at 10⁴ cells/well for SK-N-AS and 5x10³ cells/well for HEK293 and incubated at 37°C for 5 h before an extra 50 μ l/well DMEM with 10% FCS was added. At 24 h after transfection, the transfection efficiency was evaluated using fluorescence microscopy, by estimating the number of EGFP-expressing cells (green) (Fig. 1).

Cell growth assay. After transfection, the cells were divided into 96-well plates. Cells with each different construct were divided into 4 wells/plate, in 3 different plates with 10⁴ cells in 100 μ l DMEM 10% FCS per well. The cells were incubated for 1-3 days at 37°C; one plate was used every day for 3 days after transfection to monitor cell growth. Twenty μ l of CellTiter96 Aqueous One Solution (Cell Proliferation Assay, Promega, Madison, WI) was added to each well and incubated in a humid dark chamber at 37°C for 2-4 h. The absorbance was detected at 490 nm by an ELISA-reader (Labsystems Multiscan RC). The results were compared to a standard curve to calculate the number of live cells per well each day. The mean number of cells in the 4 wells evaluated per day per construct was used in evaluating the results.




Figure 1. Cells transfected with 1 μ g of cytoplasmic EGFP or nuclear EGFP in 10^5 HEK293 cells or 2×10^5 SK-N-AS cells. By fluorescent microscopy, it is possible to detect the difference in localization of EGFP in the cytoplasm (left panels), or in the nucleus (right panels).

Experiments comparing different mRNA and mRNA-concentrations were performed from the same batch of cells and treated equally throughout the experimental procedure.

Results and discussion

The transfection efficiency of EGFP-mRNA, using Lipofectamine 2000, for both cell lines was 80-90% as determined by fluorescence microscopy 24 h after transfection. By cell counting, we determined the average cell viability to 89% in EGFP-transfected SK-N-AS cells compared to untreated cells 24 h after transfection. For HEK293 cells, this number was 59%. Thus, HEK293 cells were more sensitive to this treatment. By fluorescence microscopy, we also detected a clear difference in the cytoplasmic EGFP-mRNA and the nuclear NLS-EGFP-mRNA transfections; in the NLS-EGFP transfections, the nucleus was clearly stained green, whereas the generally used EGFP showed an even green stain in the entire cell (Fig. 1). This proves that the nuclear localization signal (NLS) is working.

In order to be able to functionally screen genes in cell lines, full-length *in vitro*-transcribed mRNA can be created for each gene. The use of mRNA instead of expression cDNA vectors results in both an increase in the transfection efficiency and eliminates the need for cloning. This is a relatively easy way to functionally test genes where the full-length cDNA construct is not available, with the exception of very large genes which could have a problem providing good PCR-product yields.

We detected a major difference in cell toxicity between cytoplasmic EGFP, the EGFP generally used, and an EGFP molecule that we constructed including a nuclear localization signal (NLS), nuclear EGFP. In both cell types, we detected an approximate 6-fold difference in the number of viable cells 48 h after transfection when 1 μ g mRNA of EGFP respectively NLS-EGFP was used, with the nuclear NLS-EGFP showing lower cell growth (Fig. 2). This was an intriguing




Figure 2. Cell growth curves of transfected SK-N-AS cells (at the top) and HEK293 cells (at the bottom). Three different concentrations (1, 0.1, 0.01 μ g per 2×10^5 cells) for three different mRNAs: cytoplasmic EGFP (EGFP), nuclear EGFP (NLS-EGFP) and a non-sense-NLS-construct (Nonsense), and a Lipofectamine 2000-only control with no mRNA (Lipofectamine only). Viable cells were counted 24, 48 and 72 h after transfection.

finding, indicating that these cells were more sensitive to EGFP located in the nucleus than to EGFP in the cytoplasm. The cytoplasmic EGFP, on the other hand, did not seem to affect the cell viability to any extent. In order to eliminate this difference between cytoplasmic and nuclear EGFP, the mRNA-concentration needed to be very low: 10 ng in 2×10^5 cells. This was the same for both SK-N-AS and HEK293 cells (Fig. 3). It is questionable whether these very low concentrations are effective, since the Lipofectamine-only control showed the same results as the experiments with mRNA (Figs. 2 and 3).

In order to use this method for functional evaluation of nuclear proteins, we found the need to develop a molecule that would have a nuclear localization but not such a devastating effect on cell viability as NLS-EGFP. We constructed mRNA with the same NLS-sequence (MVPKPKRKVED) as NLS-




Figure 3. Number of viable SK-N-AS cells (at the top) and HEK293 cells (at the bottom) 72 h after transfection of different concentrations of *in vitro*-transcribed mRNA, indicated on the x-axis (at ng per 10^2 cells). Three different mRNAs have been used: cytoplasmic EGFP (EGFP), nuclear EGFP (NLS-EGFP) and a nonsense-NLS-construct (Nonsense), Lipofectamine 2000-only control with no mRNA (Lipofectamine only), and untreated cells. The mRNA-concentration where cytoplasmic EGFP-treated cells and nonsense-NLS-treated cells are equally affected is indicated with a dotted line.

EGFP but with a short truncated peptide (PMVSKGEELFTG) added to the NLS-peptide. In order to easily compare the different mRNA-constructs, we used the same EGFP-vector (pIRES-EGFP) as a base in the construction of the nonsense-NLS-construct.

We detected a difference in cell viability after transfection of cytoplasmic EGFP, NLS-EGFP and the nonsense-NLS-construct. The nonsense-mRNA was more toxic to the cells than the cytoplasmic EGFP but less toxic than NLS-EGFP, as expected; the higher the mRNA-concentration, the larger the difference in cell growth after transfection (Fig. 3). A cut-off concentration, where the nonsense-NLS-construct did not have a more negative effect on cell viability than cytoplasmic EGFP had, was evaluated to approximately 100 ng/ 10^5 cells for both cell types (Fig. 3). HEK293 cells were generally more sensitive to this treatment than SK-N-AS cells were,




Figure 4. Cell growth curves of transfected SK-N-AS (left) and HEK293 cells (right), transfected with six different *in vitro* mRNAs: *PGD*, *CORT*, *DFFA*, *PEX14*, Non-sense and *EGFP* at 0.1 ng/ 10^2 cells. Viable cells were counted 24, 48 and 72 h after transfection. *PEX14* significantly ($p=0.03$) reduces cell proliferation in both cell lines and *DFFA* significantly ($p=0.04$) reduces cell proliferation in SK-N-AS cells compared to the Nonsense experiment, whereas *PGD* and *CORT* do not have any significant effect.

but the cut-off concentration was the same per cell for both cell types.

In order to evaluate the method, we used four known human mRNAs encoding proteins with different functions and cell localization. All four genes are localized to the same chromosomal region, 1p36.2, a region that is hemizygotously deleted in SK-N-AS cells (25) but not in HEK293 cells. One of the genes, *PEX14*, had a significant reduction in cell proliferation 48-72 h after transfection in both cell lines (Table I, Fig. 4). *Pex14* is a peroxisomal protein (22,23) that also includes a nuclear localization signal and can inhibit transcriptional activation (19). Whether the effect on cell proliferation in these cells is due to the specific activity of this gene needs further investigation. *DFFA* had an effect on cell proliferation in the 1p deleted cell line, SK-N-AS, but not in HEK293 cells (Table I, Fig. 4). *DFFA*, a gene product of *DFFA*, is a cytosolic protein that needs to be activated by caspase-3 to trigger DNA fragmentation during apoptosis (20). The effect of *DFFA* is dependent on the status of caspase-3 in the cells, which might differ between SK-N-AS and HEK293 cells. Also, the fact that SK-N-AS cells have lost one copy of this gene could explain the difference in effect on cell proliferation between SK-N-AS and HEK293 cells. The other two genes, *PGD* and *CORT*, did not have any effect on cell proliferation (Table I, Fig. 4). *PGD* encodes an enzyme in the pentose phosphate shunt, and *CORT* encodes Cortistatin, a hormone-like neuropeptide (21); neither



SPANDIDOS PUBLICATIONS effects of *in vitro*-transcribed mRNA (100 ng/10⁵ cells) on cell proliferation after transfection into SK-N-AS and cell lines, compared to non-sense-mRNA.^a

mRNA	Hours after transfection	SK-N-AS		HEK293	
		% difference in average number of cells compared to nonsense-mRNA	p-value t-test	% difference in average number of cells compared to nonsense-mRNA	p-value t-test
<i>PGD</i>	24	-5	ns	45	0.02
	48	-3	ns	13	ns
	72	-16	ns	-6	ns
<i>CORT</i>	24	-8	ns	42	0.02
	48	4	ns	17	ns
	72	-6	ns	-7	ns
<i>DFFA</i>	24	-9	ns	23	ns
	48	-11	0.02	8	ns
	72	-35	0.04	-8	ns
<i>PEX14</i>	24	-20	ns	4	ns
	48	-19	0.04	-35	0.03
	72	-36	0.03	-53	0.0005

^aFor each experiment p-values (Student's two-sided t-test) are indicated to the right. ns, not significant.

of these two proteins are nuclear. These results show a difference in cell proliferation between different genes using this method. Further investigations are needed to prove that these effects are due to the specific activity of the genes in question and not to the cellular localization of the gene products.

This method is robust and the results are reproducible and show the same differences between different constructs if the experiment is repeated. This method is relatively easy to use, and no special equipment is needed, except a tissue culture- and a PCR-facility; equipment that most laboratories have. The method can be used to evaluate how different genes affect cell viability, and we believe that the nonsense-NLS-construct can generally be used as a control, even though the best control will always be a mutated null-function variant of the gene that is tested.

By using newly trypsinized cells in suspension and Lipofectamine 2000, we obtained a transfection efficiency of *in vitro*-transcribed mRNA of 80-90% in both SK-N-AS and HEK293 cells. We also evaluated the different effects of cytoplasmic EGFP and nuclear EGFP, where the nuclear EGFP is significantly more toxic to the cells compared to the cytoplasmic EGFP. In order to develop a null experiment for functional tests of nuclear proteins, we constructed a short non-functional mRNA including an NLS, and evaluated the concentrations at which mRNA encoding nuclear proteins can be added without general toxicity, depending on the fact that the proteins are localized to the nucleus. This method is relatively easy and possible for most laboratories since no special equipment is required.

Acknowledgements

We gratefully acknowledge the financial support of the Swedish Cancer Society, the Children's Cancer Foundation, the King Gustav V Jubilee Clinic Cancer Research Foundation,

the Assar Gabrielsson Foundation, Svenska Läkaresällskapet and Lars Hiertas Minne. The work was also partially supported by a grant from the Brockhoff Foundation to P.I.

References

1. Tyers M and Mann M: From genomics to proteomics. *Nature* 422: 193-197, 2003.
2. Carpenter AE and Sabatini DM: Systematic genome-wide screens of gene function. *Nat Rev Genet* 5: 11-22, 2004.
3. Recillas-Targa F: Gene transfer and expression in mammalian cell lines and transgenic animals. *Methods Mol Biol* 267: 417-433, 2004.
4. Elouahabi A and Ruyschaert JM: Formation and intracellular trafficking of lipoplexes and polyplexes. *Mol Ther* 11: 336-347, 2005.
5. Uchida E, Mizuguchi H, Ishii-Watabe A and Hayakawa T: Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells. *Biol Pharm Bull* 25: 891-897, 2002.
6. Gitlin L, Karelsky S and Andino R: Short interfering RNA confers intracellular antiviral immunity in human cells. *Nature* 418: 430-434, 2002.
7. Lechardeur D, Sohn KJ, Haardt M, Joshi PB, Monck M, Graham RW, Beatty B, Squire J, O'Brodovich H and Lukacs GL: Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. *Gene Ther* 6: 482-497, 1999.
8. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N and Verkman AS: Size-dependent DNA mobility in cytoplasm and nucleus. *J Biol Chem* 275: 1625-1629, 2000.
9. Malone RW, Felgner PL and Verma IM: Cationic liposome-mediated RNA transfection. *Proc Natl Acad Sci USA* 86: 6077-6081, 1989.
10. Bettinger T, Carlisle RC, Read ML, Ogris M and Seymour LW: Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. *Nucleic Acids Res* 29: 3882-3891, 2001.
11. Ponsaerts P, van der Sar S, van Tendeloo VF, Jorens PG, Berneman ZN and Singh PB: Highly efficient mRNA-based gene transfer in feeder-free cultured H9 human embryonic stem cells. *Cloning Stem Cells* 6: 211-216, 2004.
12. Smits E, Ponsaerts P, Lenjou M, Nijs G, van Bockstaele DR, Berneman ZN and van Tendeloo VF: RNA-based gene transfer for adult stem cells and T cells. *Leukemia* 18: 1898-1902, 2004.

13. Chalfie M, Tu Y, Euskirchen G, Ward WW and Prasher DC: Green fluorescent protein as a marker for gene expression. *Science* 263: 802-805, 1994.
14. Zhang G, Gurtu V and Kain SR: An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. *Biochem Biophys Res Commun* 227: 707-711, 1996.
15. Zanta MA, Belguise-Valladier P and Behr JP: Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. *Proc Natl Acad Sci USA* 96: 91-96, 1999.
16. Douglas GR, McAlpine PJ and Hamerton JL: Regional localization of loci for human PGM and 6PGD on human chromosome one by use of hybrids of Chinese hamster-human somatic cells. *Proc Natl Acad Sci USA* 70: 2737-2740, 1973.
17. Ejeskär K, Abel F, Sjöberg R, Backström J, Kogner P and Martinsson T: Fine mapping of the human prepro corticotropin gene (CORT) to neuroblastoma consensus deletion region 1p36.3→p36.2, but absence of mutations in primary tumors. *Cytogenet Cell Genet* 89: 62-66, 2000.
18. Leek JP, Carr IM, Bell SM, Markham AF and Lench NJ: Assignment of the DNA fragmentation factor gene (DFFA) to human chromosome bands 1p36.3→p36.2 by *in situ* hybridization. *Cytogenet Cell Genet* 79: 212-213, 1997.
19. Gavva NR, Wen SC, Daftari P, Moniwa M, Yang WM, Yang-Feng LP, Seto E, Davie JR and Shen CK: NAPP2, a peroxisomal membrane protein, is also a transcriptional corepressor. *Genomics* 79: 423-431, 2002.
20. Liu X, Zou H, Slaughter C and Wang X: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. *Cell* 89: 175-184, 1997.
21. De Lecea L, Criado JR, Prospero-Garcia O, Gautvik KM, Schweitzer P, Danielson PE, Dunlop CL, Siggins GR, Henriksen SJ and Sutcliffe JG: A cortical neuropeptide with neuronal depressant and sleep-modulating properties. *Nature* 381: 242-245, 1996.
22. Albertini M, Rehling P, Erdmann R, Girzalsky W, Kiel JA, Veenhuis M and Kunau WH: Pex14p, a peroxisomal membrane protein binding both receptors of the two PTS-dependent import pathways. *Cell* 89: 83-92, 1997.
23. Will GK, Soukupova M, Hong X, Erdmann KS, Kiel JA, Dodt G, Kunau WH and Erdmann R: Identification and characterization of the human orthologue of yeast Pex14p. *Mol Cell Biol* 19: 2265-2277, 1999.
24. Thomas P and Smart TG: HEK293 cell line: a vehicle for the expression of recombinant proteins. *J Pharmacol Toxicol Methods* 51: 187-200, 2005.
25. Van Roy N, Jauch A, van Gele M, Laureys G, Versteeg R, De Paepe A, Cremer T and Speleman F: Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. *Cancer Genet Cytogenet* 97: 135-142, 1997.